Candesartan cilexetil is an angiotensin II receptor antagonist, and candesartan, its active metabolite, is metabolized by CYP2C9. However, the effect of CYP2C9*3 on candesartan metabolism is not established. We characterized the kinetics of candesartan by CYP2C9*1/*1 and CYP2C9*1/*3 in human liver microsomes. The difference between the two was not significant. Subsequently, CYP2C9*1 and CYP2C9*3 (Leu 359 ) were expressed in yeast, and the kinetics of candesartan were determined. The wild-type showed the lower K m (345 vs 439 M; 3/4) and higher V max /K m (1/3) than the Leu 359 variant. Also, we investigated potential interaction between candesartan and warfarin with both the wild-type and the Leu 359 variant. Candesartan had no effect on S-warfarin 7-hydroxylation. In contrast, S-warfarin inhibited candesartan metabolism by the wild-type (K i = 17 M) greater than by the Leu 359 variant (K i = 36 M). These findings suggest that CYP2C9*3 may change not only the metabolic activity but also the inhibitory susceptibility compared with
INTRODUCTION
Candesartan cilexetil, an oral nonpeptide angiotensin II antagonist, is widely used in the treatment of hypertension. Candesartan cilexetil is an ester prodrug which is completely converted into its active metabolite, candesartan during gastrointestinal absorption. 1 Candesartan is metabolised to the inactive compound M-II via the cytochrome P450 (CYP) 2C9-mediated pathway.
2 CYP2C9 is one of the major drug metabolizing enzymes in humans, and metabolizes clinically important drugs. 3 Three genetic polymorphisms of CYP2C9 with an amino acid change have been known to exist in individuals:
4 CYP2C9*1 (Arg144, Ile359; Ile 359 ), CYP2C9*2 (Cys144, Ile359), CYP2C9*3 (Arg144, Leu359; Leu 359 ). However, the CYP2C9*2 polymorphism is not detected in some ethnic groups, for example Japanese. 5 Moreover, it is unknown whether CYP2C9*2 would have a significant effect on its catalytic activity. On the other hand, previous in vivo studies showed that individuals who were genotyped as CYP2C9*3 reduced the clearance of S-warfarin, tolbutamide and phenytoin. [6] [7] [8] Also, expression systems of CYP enzymes have been used to investigate the catalytic activities of the enzymes in vitro, and the Leu 359 variant significantly affected the kinetic parameters in vitro, such as S-warfarin, 9 tolbutamide 7 and torsemide. 10 However, there has been no study on the CYP2C9 catalytic property of candesartan. Therefore, we studied the kinetic analysis for candesartan by homozygous CYP2C9 Values were the mean from two independent experiments. K m and K i , M; V max , nmol min 
In vitro Inhibition
The difference in the inhibitory tendency of candesartan between the wild-type and the Leu 359 variant expressed in yeast on the metabolism of S-warfarin was confirmed by measuring the 7-hydroxywarfarin concentration ( Figure 1) . Candesartan showed no effect on S-warfarin hydroxylation. In contrast, the difference in the inhibitory tendency of Swarfarin and R-warfarin between the wild-type and the Leu 359 variant on the metabolism of candesartan was con- (Table 1) . There were few differences in the kinetic parameters between the two. Sub- [13] [14] [15] These findings indicate that the influence of the Leu 359 variant on the metabolism of candesartan is lower than that of other CYP2C9 substrates. 16 Also, in vitro inhibition study showed that candesartan did not inhibit Swarfarin hydroxylation (Figure 1 ). In addition, recent studies have shown that the K i value of candesartan on tolbutamide hydroxylation in human liver microsomes was 155 M 17 and the maximal plasma concentration of candesartan was less than 1 M.
DISCUSSION
2 Therefore, it is suggested that candesartan barely inhibits CYP2C9-mediated metabolism of other CYP2C9 substrates.
S-warfarin inhibited the metabolism of candesartan by the wild-type more potently than by the Leu 359 variant (Figure 2a) , and the K i values were shown in Table 2 . However, we calculated that there were few changes in the maximal plasma concentration of candesartan by the inhibition (data not shown). Since the Leu 359 variant has a higher K m value than the wild-type for S-warfarin metabolism (Table 2 and Takahashi et al 18 ), it is suggested that the change in the affinity of S-warfarin caused by the substitution Ile 359 to Leu 359 produced the difference in the inhibitory effect. In contrast, R-warfarin scarcely inhibited the Ile 359 -and the Leu 359 -mediated metabolism of candesartan, and both IC 50 values were greater than 100 M (Figure 2b ). R-warfarin showed noncompetitive-type inhibition in the wild-type with K i value of 97 M (unpublished data). A recent study reported that CYP2C9 had a markedly higher K m (more than 10 000 M) for R-warfarin metabolism. 7 The affinity to CYP2C9 may contribute to potential interactions with competitive inhibition.
The present study is the first report describing the kinetic properties of candesartan by CYP2C9 in view of the genetic polymorphism. In conclusion, the influence of CYP2C9*3 for candesartan metabolism is not significant. Furthermore, it is suggested that the affinity of CYP2C9 contributes not only to metabolic activity but also to inhibitory potency. This finding also corresponds with the finding that the Leu 359 variant is less sensitive to inhibition by S-warfarin than the wild-type. In these points, it is important to clarify the affinity of the Leu 359 variant for different CYP2C9 substrates and inhibitors. Furthermore, the present findings indicate that polymorphism of other drug metabolizing enzymes may have an influence on the inhibitory potency. The major CYP isoforms which have high mutant allelic frequencies, for instance CYP2D6 and CYP2C19, should especially be taken into consideration.
MATERIALS AND METHODS

Chemicals
Candesartan cilexetil and its two metabolites (candesartan and M-II) were from Takeda Chemical Industries (Osaka, Japan). NADPH was purchased from Oriental Yeast Co (Tokyo, Japan). Other reagents and organic solvents were obtained from Wako Pure Chemical Industries (Tokyo, Japan). The expression vector pGYR1, which has a GAPDH promoter and includes the yeast NADPH-P450 reductase gene, 19 was supplied by Dr Yabusaki of Sumitomo Chemical Co (Osaka, Japan). Human liver microsome, S-warfarin, Rwarfarin, and 7-hydroxywarfarin were purchased from Daiichi Pure Chemicals Co (Tokyo, Japan).
Construction and Expression of CYP2C9 cDNAs in
Saccharomyces cerevisiae
The full length CYP2C9*1 cDNA was isolated from human liver cDNA library using the polymerase chain reaction (PCR). PCR based site-mutagenesis was carried out to construct CYP2C9*1 and CYP2C9*3 cDNAs. CYP2C9*1 and CYP2C9*3 cDNAs cut out with HindIII were each subcloned into the expression vector pGYR1. 20 The pGYR1 vectors containing CYP2C9 cDNAs were transformed into the Saccharomyces cerevisiae AH 22 strain. 21 
Determination of Metabolites
Candesartan metabolic activity was measured according to the method of Miyabayashi et al 22 with some modifications. The mixture (0.20 ml) containing 10 pmol of P450 protein www.nature.com/tpj (in case of human liver microsome, 0.5 mg of protein ml −1 ) and 1 mM NADPH in 0.05 M potassium phosphate buffer (pH 7.4) was incubated with candesartan (final concentration of 1-500 M) at 37°C after 3 min of preincubation without NADPH. The incubation continued with gentle shaking at 37°C for 30 min and the reaction was stopped with methanol (200 l). Denatured protein was precipitated by centrifugation and the supernatant (100 l) was analyzed by HPLC with a reverse-phase column (Inertsil ODS-3, 4.6 × 150 mm, GL Science, Tokyo, Japan). The column temperature was set at 40°C. The mobile phase A and B were composed of 10 mM potassium dihydrogenphosphate/ acetonitrile (80:20, v/v for A; 50:50, v/v for B). The gradient elution mode was adopted. The gradient used was liner from 0-60% of the mobile phase B concentration. M-II was detected using a fluorescent detector (Nanospace SI-1, Shiseido, Tokyo, Japan) with excitation/emission wavelengths at 270/390 nm.
S-warfarin 7-hydroxylation activity was measured by the addition of S-warfarin in the reconstituted system. Reactions continued with gentle shaking at 37°C for 15 min and other conditions for incubation and deproteinization were as for the assay of candesartan metabolic activity. It was analyzed by HPLC with a reverse-phase column (J's sphere ODS H-80, 4.6 × 150 mm, YMC, Kyoto, Japan). The column temperature was set at 30°C. The mobile phase was composed of H 2 O/acetonitrile (62:38) containing 0.5% phospholic acid and was delivered at a flow rate of 1.3 ml min −1
. 7-Hydroxywarfarin was detected at a wavelength of 230 nm using a UV detector (SPD 10-A, SHIMADZU, Kyoto, Japan).
